Skip to content
Menu
Find Partners
Ion Channel World Map
Companies
Labs
Nonprofits
Resources
Ion Channel Overview
Fundamentals
Ion Channel Drugs
Interviews
Analytics
Expert opinions
Books
Infographics
Journal Covers
Quotes
External Resources
Blog
Menu
Find Partners
Ion Channel World Map
Companies
Labs
Nonprofits
Resources
Ion Channel Overview
Fundamentals
Ion Channel Drugs
Interviews
Analytics
Expert opinions
Books
Infographics
Journal Covers
Quotes
External Resources
Blog
Industry
-
12/10/2022
NMD Pharma Reports Positive Data from a Phase I/IIa Clinical Trial of its ClC-1 Chloride Ion Channel Inhibitor NMD670 in Patients with Myasthenia Gravis
Source: NMD Pharma
Industry
-
01/10/2022
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of IND Application for NP-300 (Lechlemer)
Source: Jaguar Health
Industry
-
28/09/2022
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis
Source: NMD Pharma
